Novavax (NVAX) Free Cash Flow Growth (5y) (2015 - 2026)
Powered by 
Analysis
Novavax (NVAX) Free Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Novavax | 1.67 Bn | 951.85 Mn | 42.45 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.76% |
| Mar 31, 2026 | -15.46% |
| Dec 31, 2025 | 24.61% |
| Sep 30, 2025 | 55.15% |
| Jun 30, 2025 | -25.75% |
| Mar 31, 2025 | -51.77% |
| Dec 31, 2024 | -48.85% |
| Sep 30, 2024 | -34.99% |
| Jun 30, 2024 | 64.95% |
| Mar 31, 2024 | -11.96% |
| Dec 31, 2023 | -32.31% |
| Sep 30, 2023 | -11.26% |
| Jun 30, 2023 | -34.74% |
| Mar 31, 2023 | -39.14% |
| Dec 31, 2022 | -26.17% |
| Sep 30, 2022 | -6.89% |
| Jun 30, 2022 | -70.32% |
| Mar 31, 2022 | -18.24% |
| Sep 30, 2021 | 5.90% |
| Jun 30, 2021 | 31.37% |